Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality?: Did close examination of the trees obscure our view of the wood?

AIDS

Volumn 24, Issue SUPPL. 5, 2010, Pages

  Grant, Alison D ^a   Fielding, Katherine L ^a   Charalambous, Salome ^b   Chaisson, Richard E ^c   Churchyard, Gavin J ^a,b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b AURUM INSTITUTE   (South Africa)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

CD4 LYMPHOCYTE COUNT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; NOTE; PRIORITY JOURNAL; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV-1; HUMANS; ISONIAZID; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TUBERCULOSIS; VIRAL LOAD;

EID: 78649287933     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000391011.40892.ff     Document Type: Note

References (23)

1. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010:CD000171.
2. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342:268-272.
3. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997; 337:801-808.
4. Hawken MP, Meme HK, Elliott LC, Chakaya JM, Morris JS, Githui WA, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS 1997; 11:875-882.
5. Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12:2447-2457.
6. Fitzgerald DW, Severe P, Joseph P, Mellon LR, Noel E, Johnson WD Jr, et al. No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial. J Acquir Immune Defic Syndr 2001; 28:305-307.
7. Gordin FM, Matts JP, Miller C, Brown LS, Hafner R, John SL, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997; 337:315-320.
8. Rivero A, Lopez-Cortes L, Castillo R, Lozano F, Garcia MA, Diez F, et al. Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy. Enferm Infecc Microbiol Clin 2003; 21:287-292.
9. Churchyard GJ, Kleinschmidt I, Corbett EL, Murray J, Smit J, De Cock KM. Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4:705-712.
10. Ackah AN, Coulibaly D, Digbeu H, Diallo K, Vetter KM, Coulibaly I-M, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire. Lancet 1995; 345:607-610.
11. Connolly C, Davies GR, Wilkinson D. Impact of the human immunodeficiency virus epidemic on mortality among adults with tuberculosis in rural South Africa, 1991-1995. Int J Tuberc Lung Dis 1998; 2:919-925.
12. Van Den Broek J, Mfinanga S, Moshiro C, O'Brien R, Mugomela A, Lefi M. Impact of human immunodeficiency virus infection on the outcome of treatment and survival of tuberculosis patients in Mwanza, Tanzania. Int J Tuberc Lung Dis 1998; 2: 547-552.
13. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897-1908.
14. Lucas SB, Hounnou A, Peacock C, Beaumel A, Djomand G, N'Gbichi JM, et al. The mortality and pathology of HIV infection in a west African city. AIDS 1993; 7:1569-1579.
15. Rana FS, Hawken MP, Mwachari C, Bhatt SM, Abdullah F, Ng'ang'a LW, et al. Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. J Acquir Immune Defic Syndr 2000; 24:23-29.
16. Ansari NA, Kombe AH, Kenyon TA, Hone NM, Tappero JW, Nyirenda ST, et al. Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997- 1998. Int J Tuberc Lung Dis 2002; 6:55-63.
17. Murray J, Sonnenberg P, Nelson G, Bester A, Shearer S, Glynn JR. Cause of death and presence of respiratory disease at autopsy in an HIV-1 seroconversion cohort of southern African gold miners. AIDS 2007; 21 (Suppl 6):S97-S104.
18. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, et al. The impact of antiretroviral therapy and iso-niazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21: 1441-1448.
19. Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009; 23:631-636.
20. Lawn SD, Wood R. Incidence of tuberculosis during highly active antiretroviral therapy in high-income and low-income countries. Clin Infect Dis 2005; 41:1783-1786.
21. Grant AD, Bansi L, Ainsworth J, Anderson J, Delpech V, Easterbrook P, et al. Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? AIDS 2009; 23:2507-2515.
22. Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune recon-stitution and 'unmasking' of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008; 177:680-685.
23. CharalambousS, Grant AD, InnesC,Hoffmann CJ, Dowdeswell R, Pienaar J, et al. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS 2010; 24 (suppl 5): S5-S13.